Clinical trial · Interventional
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
Long-Term Follow-Up (LTFU) of Participants Treated With ADP Adoptive Cell Therapies
NCT03391778CI-TRIAL-00121438enrolling by invitationPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neoplasms | Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ADP adoptive cell therapy | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Participants receiving ADP adoptive cell therapy
- interventionNames
- Biological: ADP adoptive cell therapy
Primary outcomes (1)
- measure
- Number of participants with delayed adverse events (AEs) and serious adverse events (SAEs)
- timeFrame
- 15 years post last treatment
- description
- AEs will be collected.
Secondary outcomes (5)
- measure
- Number of participants with Vesicular Stomatitis Virus G protein (VSV-G) Deoxyribonucleic acid (DNA) copies in peripheral blood samples
- timeFrame
- 15 years
- description
- Peripheral blood samples will be collected for the assessment of VSV-G DNA copies.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Participants who have received at least one dose of ADP adoptive cell therapy agent. * Participants who have completed ADP sponsored or supported interventional study or have withdrawn from it. * Participants who have completed treatment as part of managed access to a GSK adoptive cell therapy. * Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. * The investigator is responsible for review of medical history. * Capable of giving signed informed consent. Exclusion Criteria: \- None
References
Publications (0)
Data not yet available
No reference posted for this study.